AI Terminal
HIKMA Pharmaceuticals PLC
Remuneration Information • Oct 1, 2024
4841_rns_2024-10-01_1c27dbd1-b420-48c3-8897-1b52d3613e45.html
Remuneration Information
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 4469G
Hikma Pharmaceuticals Plc
01 October 2024
Hikma Pharmaceuticals PLC
Block Listing Six Monthly Return
Date: 1 October 2024
| Name of applicant: | Hikma Pharmaceuticals PLC | ||
| Name of scheme: | Hikma Pharmaceuticals PLC 2018 Management Incentive Plan ("MIP") and Hikma Pharmaceuticals PLC 2014 Executive Incentive Plan ("EIP") (together "the Plans") | ||
| Period of return | From: 1 April 2024 | To: | 30 September 2024 |
| Balance of unallotted securities under scheme(s) from previous return: | The Plans: 312,624 Ordinary Shares of 10 pence | ||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | The Plans: 0 Ordinary Shares of 10 pence | ||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | MIP: 1,194 Ordinary Shares of 10 pence EIP: 0 Ordinary Shares of 10 pence |
||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | The Plans: 311,430 Ordinary Shares of 10 pence |
| Name of contact: | Helen Middlemist |
| Telephone number of contact: | +44(0)20 7399 2760 |
Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY)
(LEI: 549300BNS685UXH4JI75)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
BLRUPGWCUUPCURG